Functional outcomes in Spinal Cord Injury (SCI): Quality care versus cost containment

Journal of Spinal Cord Medicine

Volumn 20, Issue 1, 1997, Pages 1-7

  Ditunno Jr , John F ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSIFICATION; COST CONTROL; DISABILITY; ECONOMICS; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; QUALITY ADJUSTED LIFE YEAR; REVIEW; SPINAL CORD INJURY; TREATMENT OUTCOME;

COST CONTROL; DISABILITY EVALUATION; HUMANS; MANAGED CARE PROGRAMS; QUALITY ASSURANCE, HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 0030625648     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1080/10790268.1997.11719444     Document Type: Review

References (36)

1. Church GJ. Teaching hospitals in crisis. Time Magazine, July 17, 1995;40-2.
2. Iglehart JK. Medical and managed care. N Engl J Med 1995;332:1727-31.
3. Retchin SM, Hurley RE. The revision of government sponsored health care. Am J Med 1995;96:529-30.
4. Kassirer JP. Managed care and the morality of the market-place. N Engl J Med 1995;333:50-2.
5. Epstein A. Performance reports on quality - prototypes, problems, and prospects. N Engl J Med 1995;333:57-61.
6. Ditunno JF, Cohen ME, Formal CS, Whiteneck G. Functional outcomes. In; Stover SL, Whiteneck G, DeLisa J, eds. Spinal cord injury: clinical outcomes from the Model Systems. Gaithersburg, MD; Aspen Publications, 1995:1-21.
7. Go BK, DeVivo MJ, Richard JS. The epidemiology of spinal cord injury. In; Stover SL, Whiteneck G, DeLisa J, eds. Spinal cord injury: clinical outcomes from the Model Systems. Gaithersburg, MD; Aspen Publications, 1995;21-55.
8. Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal cord injury - a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991;324:1829-38.
9. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-11.
10. Davidoff GN, Roth EJ, Haughton JS, Ardner MS. Cognitive dysfunction in spinal cord injury patients: Sensitivity of the functional independence measure subscales vs. neuropsychologic assessment. Arch Phys Med Rehab 1990;71:326-9.
11. Ditunno JF Jr, Young W, Donovan WH, Creasey G. The international standards booklet for paraplegia (Standards for Neurological and Functional Classification of Spinal Cord Injury). Paraplegia 1994;32:70-80.
12. Marino R, Huang M, Knight P, Herbison GJ, Ditunno JF Jr, Segal M. Assessing selfcare status in quadriplegia: comparison of the quadriplegia index of function (QIF) and the functional independence measure (FIM). Paraplegia 1993;31:225-33.
13. Cohen M, Bartko J. Reliability of ISCSCI-92 for neurological classification of spinal cord injury - Reference Manual for the International Standards for Neurological and Functional Classification of Spinal Cord Injury. American Spinal Injury Association Publications 1994;59-65.
14. Marino R, Stineman M. Functional assessment in spinal cord injury. In; Top Spinal Cord Injury Rehabilitation. Aspen Publications, 1996:32-45.
15. Ragnarrson KT. Management of pulmonary, cardiovascular, and metabolic conditions after spinal cord injury. In; Stover SL, Whiteneck G, DeLisa J, eds. Spinal cord injury: clinical outcomes from the Model Systems. Gaithersburg, MD; Aspen Publishers, 1995:79-99.
16. Yarkony GM, Heinemann AW. Pressure ulcers. In; Stover SL, Whiteneck G, DeLisa J, eds. Spinal cord injury: clinical outcomes from the Model Systems. Gaithersburg, MD; Aspen Publishers, 1995:100-19.
17. Maynard FM, Karunas S, Adkins RH, Richard JS, Waring WP. Management of the neuromusculoskeletal systems. In; Stover SL, Whiteneck G, DeLisa J, eds. Spinal cord injury: clinical outcomes from the Model Systems. Gaithersburg, MD;; Aspen Publishers, 1995:145-79.
18. Stover SL. Review of forty years of rehabilitation issues in spinal cord injury. J Spinal Cord Med 1995;18:175-86.
19. DeVivo MJ, Whiteneck G, Charles ED. The economic impact of spinal cord injury. In; Stover SL, Whiteneck G, DeLisa J, eds. Spinal cord injury: clinical outcomes from the Model Systems. Gaithersburg, MD; Aspen Publishers, 1995:234-71.
20. Harvey C, Wilson JE, Greene CG, Berkowitz M. New estimates of the direct costs of traumatic spinal cord injuries: results of a nation wide survey. Paraplegia 1992;30:834-50.
21. Berkowitz M. Assessing the socioeconomic impact of improved treatment of head and spinal cord injuries. J Emerg Med 1993;II:63-7.
22. Pope AM, Tarlov AR. Disability in America: toward a national agenda for prevention. Washington DC; National Academy Press, 1991:32-41.
23. Tate D. Insurance benefits coverage for persons with spinal cord injuries: Determining differences across payOrs. J Am Paraplegia Soc 1993;16:76-80.
24. Evans RL, Hendricks RD, Connis RT, Haselkorn JK, Ries KR, Mennet TE. Quality of life after spinal cord injury: a literature critique and meta-analysis (1983-1992). J Am Paraplegia Soc 1994;17:60-6.
25. Fuhrer M. The subjective well being of people with spinal cord injury: Relationship to impairment, disability and handicap. Gaithersburg, MD; Aspen Publishers. In press, 1997.
26. Whiteneck G. Outcome evaluation and spinal cord injury. Neurorehabil 1994;2:31-41.
27. Whiteneck G. Measuring what matters: key rehabilitation outcomes. Arch Phys Med Rehab 1994;75:1073-6.
28. Tate D. Personal Communication.
29. Sjosteen BA, Lundquist C, Blomstrand C, Sullivan L, Sullivan M. The quality of life of three functional spinal cord injury subgroups in a Swedish community. Paraplegia 1990;28:476-88.
30. Stensman R. Adjustment to traumatic spinal cord injury. A longitudinal study of self-reported quality of life. Paraplegia 1994;32:416-22.
31. Glick H. Economic analysis of health care. London; Current Medical Literature Ltd., 1990:1-19.
32. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infection. N Engl J Med 1995;332:1418-24.
33. Lee TH. Cost effectiveness of tissue plasminogen activator. N Engl J Med 1995;332:1443-4.
34. Bombardier C, Eisenberg J. Looking into the crystal ball: can we estimate the lifetime cost of rheumatoid arthritis? J Rheumatology 1984;12:201-4.
35. Dougherty CJ. Quality-adjusted life years and the ethical values of health care. Am J Phys Med Rehab 1994;73:61-5.
36. Nalor D. Cost effectiveness analysis: are the outputs worth the inputs? ACP J Club 1996:124:A12-4.